105K stock options granted to Microbot Medical (MBOT) General Manager, CTO

Rhea-AI Filing Summary

Sharon Simon reported acquisition or exercise transactions in this Form 4 filing.

Microbot Medical Inc. reported that General Manager and CTO Sharon Simon was granted stock options covering 105,000 shares of common stock. According to the company’s 2020 Omnibus Performance Award Plan, 25% of the options vest and become exercisable on August 18, 2026, with the remaining 75% vesting in equal quarterly installments over the following 30 months, subject to the plan’s acceleration or forfeiture provisions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sharon Simon

(Last) (First) (Middle)

C/O MICROBOT MEDICAL INC.

175 DERBY ST., BLD. 27

(Street)

HINGHAM MA 02043

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Microbot Medical Inc. [ MBOT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Manager, CTO

3. Date of Earliest Transaction (Month/Day/Year)
02/18/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.1	02/18/2026		A		105,000		(1)	02/18/2036	Common Stock, par value $0.01 per share	105,000	$0	105,000	D

Explanation of Responses:

1. The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan, as amended (the "Plan"): (a) on August 18, 2026, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock, subject to acceleration or forfeiture pursuant to the terms of the Plan.

	/s/ Simon Sharon	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Microbot Medical (MBOT) report for Sharon Simon?

Microbot Medical reported a grant of stock options to General Manager and CTO Sharon Simon covering 105,000 shares of common stock. The award is structured under the company’s 2020 Omnibus Performance Award Plan, reflecting equity-based compensation rather than an open-market share purchase.

How many stock options did Sharon Simon receive from Microbot Medical (MBOT)?

Sharon Simon received stock options for 105,000 shares of Microbot Medical common stock. These options were reported on a Form 4 and represent a single derivative transaction categorized as a grant or award acquisition under the company’s 2020 Omnibus Performance Award Plan.

When do Sharon Simon’s Microbot Medical (MBOT) stock options start vesting?

The stock options begin vesting on August 18, 2026, when 25% of the grant becomes exercisable. After this initial cliff vesting date, the remaining 75% of the options vest in equal quarterly installments over the following 30 months, subject to plan terms.

What is the vesting schedule for the 105,000 Microbot Medical (MBOT) options?

The options vest in two stages: 25% vests and becomes exercisable on August 18, 2026, and the remaining 75% vests equally on a quarterly basis over the next 30 months. Vesting may accelerate or be forfeited under the 2020 Omnibus Performance Award Plan.

Is Sharon Simon’s Microbot Medical (MBOT) option grant an acquisition or sale?

The transaction is classified as an acquisition through a grant or award of derivative securities, not a sale. Form 4 data label it under transaction code “A” for grant, award, or other acquisition, with Sharon Simon holding the options as a direct owner.

Under which plan were Sharon Simon’s Microbot Medical (MBOT) options granted?

The options were granted under Microbot Medical’s 2020 Omnibus Performance Award Plan, as amended. This plan governs vesting terms, exercisability, and potential acceleration or forfeiture conditions that apply to the 105,000-share stock option award reported on the Form 4.